Eli Lilly (LLY): Top Healthcare Stock Pick of Claude AI

We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot).

Number of Hedge Funds: 137

Eli Lilly and Company is among the top stock picks of the Claude AI chatbot in 2026. It likes Eli Lilly and Company because it believes the company has stronger long-term advantages in the obesity drug market. It said Eli Lilly and Company controls about 60% of the U.S. obesity-drug market, while Novo Nordisk, despite being the cheaper stock, is losing market share and posted negative revenue growth. Claude also highlighted that Lilly has a U.S. trade and tariff exemption through January 2029 that Novo does not have. In addition, it believes Eli Lilly and Company has a stronger pipeline of future drugs, including oral GLP-1 treatments, and better upcoming trial readouts.

Baron Health Care Fund stated the following regarding Eli Lilly and Company in its Q1 2026 investor letter:

“Eli Lilly and Company, a global pharmaceutical company currently best known for its GLP-1 treatments for diabetes and obesity, detracted from performance. Longer term, we continue to view Lilly’s Mounjaro and Zepbound, along with its oral GLP-1 orforglipron, as best-in-class treatment options for diabetic and obese patients. We expect…. (Click Here to Read the Letter in Detail).”

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Follow Insider Monkey on Google News.